Evidence map›Paper›PMID 33228682›Full record

ArticleWorld journal of surgical oncology2020

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.

Lingyu Tian, Jiaqiang Ma, Lijie Ma, Bohao Zheng, Longzi Liu, Danjun Song, Yining Wang, Zhao Zhang, Qiang Gao, Kang Song and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. The role of PD‑1/PD‑L1 axis in liver diseases.Clinical and experimental medicine · 2025
    Review
  11. Myeloid cells in chronic liver inflammation.Cellular & molecular immunology · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lingyu TianDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Jiaqiang MaDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Lijie MaDepartment of General Surgery, Zhongshan Hospital (South), Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200083, China.
Bohao ZhengDepartment of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Longzi LiuDepartment of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330000, Jiangxi, China.
Danjun SongDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Yining WangDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Zhao ZhangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350001, Fujian, China.
Qiang GaoDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Kang SongDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. song.kang@zs-hospital.sh.cn.
Xiaoying WangDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. xiaoyingwang@fudan.edu.cn.ORCID http://orcid.org/0000-0001-5989-1539
Fudan University · CNFujian Medical University · CNNanchang University · CNShanghai Public Health Clinical Center · CN

Funding

National Natural Science Foundation of China 81572367National Natural Science Foundation of China 81772556National Natural Science Foundation of China 81802302
6 · The paper itself

Abstract

objectiveImmunotherapy targeting the programmed cell death protein-1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) pathway has been observed to be efficient in several solid tumors. We aim to investigate the prognostic significance of PD-1/PD-L1 expression profile in intrahepatic cholangiocarcinoma (ICC). MATERIALS AND

methodsWe investigated the expression of PD-1, PD-L1, CD8

resultsWe found that high proportion of tumor-infiltrating CD8

conclusionCD68

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaB7-H1 AntigenCD8-Positive T-LymphocytesHumansLigandsLymphocytes, Tumor-InfiltratingPrognosisProgrammed Cell Death 1 ReceptorB7-H1 AntigenLigandsProgrammed Cell Death 1 ReceptorImmunotherapyIntrahepatic cholangiocarcinomaProgrammed cell death protein-1Programmed cell death protein ligand 1Tumor immune micro-environment

Identifiers

PMID33228682
PMCPMC7686719
OpenAlexW3107426578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.